Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03

Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).

Change from baseline of the composite score from the Children's Dermatology Life Quality Index (CDLQI) assessment at the EOS visit to measure the quality of life and impact of skin disease in the subset of subjects 4 -16 years of age.

Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit.